Roche's flu med Xofluza drives drug resistance and may be a bad choice for kids, study says

Xofluza from Roche’s Genentech unit was approved by the FDA for patients over the age of 12, and the company is hoping the label will be expanded to include children. But a new study out of the University of Wisconsin found that the flu virus can develop mutations that confer resistance to Xofluza—and that the problem occurs most frequently in children.